Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BRD4 Inhibitors Could Be Future MCL Treatment Option

Key clinical point: Bromodomain-containing protein 4 (BRD4) inhibitors are possible future treatment candidates for mantle cell lymphoma (MCL).

Major finding: Treatment with the BRD4 inhibitor I-BET151 had a dose-dependent inhibitory effect on cell proliferation in MCL cell lines.

Study details: Researchers performed gene expression profiling and chromatin immunoprecipitation with parallel sequencing for BRD4.

Disclosures: The researchers reported having no conflicts of interest.

Citation:

Tsukamoto T et al. Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):77-89.